VEGFA and hepatocellular carcinoma: Multikinase inhibitors such as sorafenib, lenvatinib, regorafenib and cabozantinib, as well as the vascular endothelial growth factor (VEGF) inhibitor ramucirumab, are widely used clinically for the treatment of HCC [5,6,7,8].